Skip to main content

Cambrex expands US API capacity

Small molecule CDMO Cambrex is spending $50 million to expand its mid- and large-scale API manufacturing capacity in Charles City, Iowa. This is the sixth major investment at the site in the past eight years and follows on from a recent, smaller expansion at the site in Karlskroga, Sweden.

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Subscribe to Karlskroga

 

 

 

AMRI banner advert